The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.
 
Sana Intidhar Labidi-Galy
Consulting or Advisory Role - AstraZeneca
 
Manuel Rodrigues
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; MSD
 
Jose L. Sandoval
No Relationships to Disclose
 
Jean Emmanuel Kurtz
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Eisai; GlaxoSmithKline
Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline
 
Florian Heitz
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Novocure; PharmaMar; Roche
Consulting or Advisory Role - Amedes; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Novocure; PharmaMar; Roche
Research Funding - AstraZeneca; Roche
 
Anna Maria Mosconi
No Relationships to Disclose
 
Ignacio Romero
Consulting or Advisory Role - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; Roche
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
 
Regina Berger
No Relationships to Disclose
 
Shoji Nagao
Speakers' Bureau - AstraZeneca; Chugai Pharma; Mochida Pharmaceutical Co. Ltd.; MSD
 
Ignace Vergote
Consulting or Advisory Role - Agenus; Akesobio - China; Amgen (Inst); AstraZeneca; Britol Myers Squibb; Carrick Therapeutics (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai; Elevar Therapeutics; Genmab (Inst); GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Mersana; Millennium (Inst); MSD; Novartis; Novocure; Octimet (Inst); Oncoinvent; Roche; Seagen; Sotio; Verastem (Inst); Zentalis
Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD/Merck; Roche; Tesaro
 
Gabriella Parma
No Relationships to Disclose
 
Trine Jakobi Nøttrup
No Relationships to Disclose
 
Etienne Rouleau
Honoraria - AstraZeneca (Inst); BMS (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS
 
Georges Garnier
No Relationships to Disclose
 
Ahmed El-Balat
No Relationships to Disclose
 
Claudio Zamagni
Honoraria - Istituto Gentili; Pierre Fabre; Takeda; Teva
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Eisai; Lilly; Novartis; Pfizer; PharmaMar; QuintilesIMS; Roche; Tesaro
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Istituto Gentili (Inst); Medivation (Inst); Morphotek (Inst); Novartis (Inst); pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Roche/Genentech (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst); Tesaro (Inst); TEVA (Inst)
Travel, Accommodations, Expenses - Celgene; Istituto Gentili; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche; Tesaro
 
Cristina Martín-Lorente
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD Oncology
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
Eric Pujade-Lauraine
Employment - Arcagy-Gineco
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - AstraZeneca; Incyte; Merck; Roche
Research Funding - AstraZeneca (Inst)
Other Relationship - Arcagy-Gineco
 
Alice Fiévet
No Relationships to Disclose
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; BMS; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Roche; Seagen; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES